Answers are grounded in this paper and cite their sources.
Chronic myeloid leukemia (CML) is effectively treated with small molecule BCR::ABL1 tyrosine kinase inhibitors (TKIs) but as in all cancers, early identification of suboptimal responders and non-responders is a challenge. Through mass cytometry analysis of peripheral blood leukocytes collected on the first day of TKI treatment, we generated high-dimensional single-cell data from de novo chronic phase CML patients enrolled in two multicenter clinical trials (clinicaltrials.gov: NCT01725204 and NCT01061177). In leukocytes, dasatinib and nilotinib inhibited intracellular signaling within 1 or 3 h after first oral dose, respectively, and each TKI had a unique signaling signature reflecting its kinase specificity profile beyond BCR::ABL1. From these data, an immune and signaling profile was constructed for each patient that predicted the treatment response (BCR::ABL1 IS , %) during the first 12 months of treatment. The predictive features were drug specific: response to dasatinib was dominated by leukemic burden, neutrophil maturity (pSTAT3 Y705) and immune effector activity (pERK ½ in T- and NK cells), whereas response to nilotinib was driven by the intrinsic signaling states of CD34 + CD38 low CD25 + LSC-like cells (cleaved caspase-3, pCRKL Y207 and STAT3 [total and Y705]). These results show that single cell immune and signaling profiles measured within hours of first dose can predict 12-month treatment response, anticipating future optimization of kinase inhibitor treatment within days rather than months.
No takes yet. Share an insight, caveat, or question.
Gullaksen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: